Skip to main content

Lupin Pharmaceuticals Inc.

7 ongoing recalls and 116 historical records

Based on the official records currently available to Public Health Trace, 7 recalls naming Lupin Pharmaceuticals Inc. are currently shown as ongoing. The other 116 records below are historical.

Public Health Trace has 123 recalls naming Lupin Pharmaceuticals Inc. as the recalling firm, republished from official FDA and USDA sources.

Recall records - 123 total

Recalls by year

A bar chart of the number of recalls naming this company by year.

Recalls by year
YearRecalls
20181
201925
202019
202111
202214
20235
202414
20257
20264
Download CSV

FDA Recall TerminatedTerminated: August 18, 2020Historical recordClass I

Ceftriaxone for Injection USP, 1 g, packaged in a) one Single Use Vial (NDC 68180-633-01) and b) 10 Single Use Vials per box (NDC 68180-633-10); Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., 111 South Calvert Street, Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Mandideep 462 046 INDIA.

by Lupin Pharmaceuticals Inc.

Reason
Presence of Particulate Matter: Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials.
Published
January 16, 2019
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: August 18, 2020Historical recordClass I

Ceftriaxone for Injection USP, 500 mg, packaged in a) one Single Use Vial (NDC 68180-622-01) and b) 10 Single Use Vials per box (NDC 68180-622-10); Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., 111 South Calvert Street, Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Mandideep 462 046 INDIA.

by Lupin Pharmaceuticals Inc.

Reason
Presence of Particulate Matter: Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials.
Published
January 16, 2019
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: August 18, 2020Historical recordClass I

Ceftriaxone for Injection USP, 250 mg, packaged in a) one Single Use Vial (NDC 68180-611-01) and b) 10 Single Use Vials per box (NDC 68180-611-10); Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., 111 South Calvert Street, Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Mandideep 462 046 INDIA.

by Lupin Pharmaceuticals Inc.

Reason
Presence of Particulate Matter: Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials.
Published
January 16, 2019
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: December 16, 2019Historical recordClass III

Testosterone Topical Solution, 30mg/1.5mL, 110mL bottles, Rx only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited Pithampur (M.P.) 454 775 INDIA, NDC 68180-943-11

by Lupin Pharmaceuticals Inc.

Reason
Defective Container: Repetitive complaints received indicating pump not working.
Published
October 31, 2018
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: October 15, 2019Historical recordClass II

Lisinopril Tablets USP, 10mg, 1000-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, Maryland 21202, NDC 68180-980-03

by Lupin Pharmaceuticals Inc.

Reason
Presence of Foreign Substance: Product complaint was received of metal contaminant observed in one tablet.
Published
August 22, 2018
Distribution
Product was distributed to distributors,…

View recall →

FDA Recall TerminatedTerminated: December 6, 2019Historical recordClass III

Moxifloxacin Ophthalmic Solution USP, 0.5%, 5 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited Pithampur (M.P.) 454 775, INDIA, NDC 68180-422-01

by Lupin Pharmaceuticals Inc.

Reason
Failed Impurities/Degradation Specifications: An out-of-specification result in the related substance test during three month long-term stability study.
Published
August 8, 2018
Distribution
Product was distributed throughout the U…

View recall →

FDA Recall TerminatedTerminated: May 1, 2019Historical recordClass II

My Way (levonorgestrel) Tablets TWO PACK, 1.5 mg each, packaged as 2 Treatments (Two 1.5mg Levonorgestrel Tablets) per carton, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Pithampur (M.P.) - 454 775, INDIA, UPC 3 68180 85212 4.

by Lupin Pharmaceuticals Inc.

Reason
Marketed Without an Approved NDA/ANDA: 2-pack configuration did not receive appropriate regulatory approval prior to release.
Published
May 30, 2018
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: May 1, 2019Historical recordClass II

My Way (Levonorgestrel) Tablets TWO PACK, 1.5 mg each, packaged as 2 Treatments (Two 1.5mg Levonorgestrel Tablets) per carton, GAVIS Pharmaceuticals, A Lupin Group Company; Mfg. for Lupin Pharmaceuticals, Inc., Baltimore, MD 21202, UPC 3 43386-622-31 3.

by Lupin Pharmaceuticals Inc.

Reason
Marketed Without an Approved NDA/ANDA: 2-pack configuration did not receive appropriate regulatory approval prior to release.
Published
May 30, 2018
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: April 15, 2019Historical recordClass II

Lupin Cefdinir powder for Oral Suspension USP, 250 mg/5 mL in (a) 60 mL packs ( NDC 68180-723-20) and (b) 100 mL packs ( 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202

by Lupin Pharmaceuticals Inc.

Reason
Superpotent Drug
Published
April 25, 2018
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: April 15, 2019Historical recordClass III

Duloxetine Delayed-Release Capsules USP, 30 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited Goa 403 722 India, NDC 68180-295-06, UPC 368180295068

by Lupin Pharmaceuticals Inc.

Reason
Failed Dissolution Specification
Published
December 6, 2017
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: March 28, 2018Historical recordClass III

Famotidine for Oral Suspension USP, 40 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Goa 403 722 INDIA, NDC 68180-150-01

by Lupin Pharmaceuticals Inc.

Reason
CGMP Deviations
Published
September 13, 2017
Distribution
Nationwide

View recall →

FDA Recall TerminatedTerminated: January 17, 2019Historical recordClass III

Paroxetine Extended-Release Tablets USP, 12.5 mg, 30 count bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland, 21202, Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, India, NDC: 68180-647-06

by Lupin Pharmaceuticals Inc.

Reason
Failed Dissolution Specifications: out of specification observed in dissolution testing at 3 month long term stability study.
Published
July 19, 2017
Distribution
Nationwide

View recall →

Some FDA recall records on this page come from FDA's Enforcement Report database. Not every Enforcement Report record has a separate FDA.gov recall-announcement page.

This page lists recalls that name Lupin Pharmaceuticals Inc. as the recalling firm in the official source notice. It is not a safety rating, ranking, or statement that the company acted negligently. Read the full medical disclaimer.

Reconnecting to the server…

We lost the connection to the server.

Your session has expired.